Lysyl oxidase family proteins have been recognized as having key roles in fibrogenesis^1-3 and suggested to be attractive targets for antifibrotic treatment4. Inhibition of lysyl oxidase activity alleviates fibrosis by reducing fibrillar collagen cross-linking, thus potentially impeding the formation of Idiopathic pulmonary fibrosis (IPF)^4-6. Furthermore, our analyses revealed that 70-75% of the lung fibrosis patients are high LOX-expressing compared to normal lung, thus proving the high therapeutic potential of targeting lysyl oxidase enzymes for treatment of pulmonary fibrosis.